[go: up one dir, main page]

PE20060383A1 - Nuevos derivados amino de urea ciclicos como inhibidores de quinasa - Google Patents

Nuevos derivados amino de urea ciclicos como inhibidores de quinasa

Info

Publication number
PE20060383A1
PE20060383A1 PE2005000866A PE2005000866A PE20060383A1 PE 20060383 A1 PE20060383 A1 PE 20060383A1 PE 2005000866 A PE2005000866 A PE 2005000866A PE 2005000866 A PE2005000866 A PE 2005000866A PE 20060383 A1 PE20060383 A1 PE 20060383A1
Authority
PE
Peru
Prior art keywords
alkylene
alkenyl
cycloalkyl
halogen
alkyl
Prior art date
Application number
PE2005000866A
Other languages
English (en)
Inventor
Hartmut Strobel
Ruf Sven
Conception Nemecek
Stefan Guessregen
Kurt Ritter
Augustin Hittinger
Herve Bouchard
Didier Benard
Anne Lebrun
Youssef El-Ahmad
Dominique Lesuisse
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34931289&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060383(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of PE20060383A1 publication Critical patent/PE20060383A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE p ES 0-2; A ES ARILO, HETEROARILO, RADICAL DE 5-11 MIEMBROS HETEROCICLICO O CARBOCICLICO, MONOCICLICO O BICICLICO CONDENSADO SUSTITUIDO O NO; X ES UN ENLACE SENCILLO,ALQUILENO, -O-, -C(O)-, ENTRE OTROS; L1 ES UN ENLACE SENCILLO, ALQUILENO, ALQUINILENO, CICLOALQUILENO, ENTRE OTROS; R1 ES H, ALQUILO, ALQUINILO, CICLOALQUILO, ENTRE OTROS; R2 ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; R3 ES H, HALOGENO, HIDROXI, ALQUENILO, ALCOXI, ENTRE OTROS; R4, R4', R4'' Y R4''' SON CADA UNO H, HALOGENO, ALQUENILO, CICLOALQUILO, SUSTITUIDOS O NO CON ARILO, HETEROARILO, ENTRE OTROS; L2 ES UN ENLACE SENCILLO, ALQUILENO, ALQUINILENO, -O-, ENTRE OTROS; Y ES N-HETEROCICLO SATURADO, PARCIALMENTE SATURADO, O INSATURADO SUSTITUIDO O NO CON O, S, N, ENTRE OTROS; R5 ES H, HALOGENO, ALQUILO, ALQUENILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-[5-(4,4-DIMETIL-2,5-DIOXO-3-PIRIDIN-4-ILMETIL-IMIDAZOLIN-1-IL)-2-TRIFLUOROMETOXI-FENIL]-2-MORFOLIN-4-IL-ACETAMIDA; TRIFLUORO DE N-[5-(4,4-DIMETIL-2,5-DIOXO-3-PIRIDIN-4-ILMETIL-IMIDAZOLIN-1-IL)-2-TRIFLUOROMETOXI-FENIL]-2-PIRROLIDIN-1-IL-ACETAMIDA; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE IGF-1R (RECEPTOR DE FACTOR DE CRECIMIENTO SEMEJANTE A LA INSULINA 1) UTILES EN TRATAMIENTOS ONCOLOGICOS
PE2005000866A 2004-07-27 2005-07-25 Nuevos derivados amino de urea ciclicos como inhibidores de quinasa PE20060383A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04291904A EP1621536A1 (en) 2004-07-27 2004-07-27 Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Publications (1)

Publication Number Publication Date
PE20060383A1 true PE20060383A1 (es) 2006-06-06

Family

ID=34931289

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005000866A PE20060383A1 (es) 2004-07-27 2005-07-25 Nuevos derivados amino de urea ciclicos como inhibidores de quinasa

Country Status (20)

Country Link
US (1) US7759379B2 (es)
EP (2) EP1621536A1 (es)
JP (1) JP2008508228A (es)
KR (1) KR20070038529A (es)
CN (1) CN101031559A (es)
AR (1) AR050269A1 (es)
AT (1) ATE498618T1 (es)
AU (1) AU2005266460A1 (es)
BR (1) BRPI0512681A (es)
CA (1) CA2571323A1 (es)
DE (1) DE602005026395D1 (es)
EA (1) EA011088B1 (es)
IL (1) IL180286A0 (es)
MA (1) MA28732B1 (es)
MX (1) MX2007001024A (es)
NO (1) NO20071067L (es)
PE (1) PE20060383A1 (es)
TW (1) TW200616973A (es)
UY (1) UY29039A1 (es)
WO (1) WO2006010641A2 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7354933B2 (en) * 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621539A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK3100727T3 (en) 2006-03-27 2018-11-12 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
CA2678577A1 (en) * 2007-02-26 2008-09-04 Vitae Pharmaceuticals, Inc. Cyclic urea and carbamate inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1
WO2009017664A1 (en) * 2007-07-26 2009-02-05 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1
AR069207A1 (es) * 2007-11-07 2010-01-06 Vitae Pharmaceuticals Inc Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1
WO2009075835A1 (en) 2007-12-11 2009-06-18 Vitae Pharmaceutical, Inc CYCLIC UREA INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE 1
TW200934490A (en) * 2008-01-07 2009-08-16 Vitae Pharmaceuticals Inc Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1
US8592409B2 (en) * 2008-01-24 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic carbazate and semicarbazide inhibitors of 11β-hydroxysteroid dehydrogenase 1
WO2009102428A2 (en) * 2008-02-11 2009-08-20 Vitae Pharmaceuticals, Inc. 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1
EP2254872A2 (en) * 2008-02-15 2010-12-01 Vitae Pharmaceuticals, Inc. Cycloalkyl lactame derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
EP2274287B1 (en) * 2008-03-18 2016-03-09 Vitae Pharmaceuticals, Inc. Inhibitors of 11beta-hydroxysteroid dehydrogenase type 1
CA2723032A1 (en) * 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
JP5696037B2 (ja) 2008-05-01 2015-04-08 ヴァイティー ファーマシューティカルズ，インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状インヒビター
ES2421537T3 (es) * 2008-05-01 2013-09-03 Vitae Pharmaceuticals Inc Inhibidores cíclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
US8592410B2 (en) 2008-05-01 2013-11-26 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1
CA2729998A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CA2730499A1 (en) 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2010089303A1 (en) 2009-02-04 2010-08-12 Boehringer Ingelheim International Gmbh CYCLIC INHIBITORS OF 11 β-HYDROXYSTEROID DEHYDROGENASE 1
TW201039034A (en) * 2009-04-27 2010-11-01 Chunghwa Picture Tubes Ltd Pixel structure and the method of forming the same
GEP20156309B (en) * 2009-04-30 2015-07-10 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
MA33216B1 (fr) 2009-04-30 2012-04-02 Boehringer Ingelheim Int Inhibiteurs cycliques de la 11béta-hydroxysteroïde déshydrogénase 1
EP2440537A1 (en) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure
US8883778B2 (en) 2009-07-01 2014-11-11 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 beta-hydroxysteroid dehydrogenase 1
CA2774998A1 (en) 2009-09-30 2011-04-07 President And Fellows Of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
WO2011159760A1 (en) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
EP2585444B1 (en) 2010-06-25 2014-10-22 Boehringer Ingelheim International GmbH Azaspirohexanones as inhibitors of 11-beta-hsd1 for the treatment of metabolic disorders
MX2013004699A (es) 2010-11-02 2013-05-22 Boehringer Ingelheim Int Combinaciones farmaceuticas para el tratamiento de trastornos metabolicos.
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
KR20230149873A (ko) * 2014-09-29 2023-10-27 케모센트릭스, 인크. Ｃ5ａＲ 길항제의 제조 방법 및 이러한 제조에서의 중간체
US11292782B2 (en) 2018-11-30 2022-04-05 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
CN112574176B (zh) * 2019-09-27 2024-03-15 隆泰申医药科技(南京)有限公司 一种杂芳基类化合物及其应用
CN114591335B (zh) * 2021-03-29 2023-06-27 浙江大学 吲唑类化合物及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2476087A1 (fr) 1980-02-18 1981-08-21 Roussel Uclaf Nouvelles oximes derivees de l'acide 3-alkyloxy ou 3-alkyl-thiomethyl 7-amino thiazolyl acetamido cephalosporanique, leur procede de preparation et leur application comme medicaments
FR2671348B1 (fr) 1991-01-09 1993-03-26 Roussel Uclaf Nouvelles phenylimidazolidines, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant.
US5411981A (en) 1991-01-09 1995-05-02 Roussel Uclaf Phenylimidazolidines having antiandrogenic activity
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
AU2002951247A0 (en) * 2002-09-06 2002-09-19 Alchemia Limited Compounds that interact with kinases
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
US7354933B2 (en) 2003-01-31 2008-04-08 Aventis Pharma Sa Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
EP1621539A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Heterocycle -substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors

Also Published As

Publication number Publication date
KR20070038529A (ko) 2007-04-10
NO20071067L (no) 2007-04-26
BRPI0512681A (pt) 2008-04-01
JP2008508228A (ja) 2008-03-21
WO2006010641A3 (en) 2006-10-26
IL180286A0 (en) 2007-07-04
EP1773808B1 (en) 2011-02-16
UY29039A1 (es) 2006-02-24
AR050269A1 (es) 2006-10-11
ATE498618T1 (de) 2011-03-15
CA2571323A1 (en) 2006-01-02
EP1773808A2 (en) 2007-04-18
WO2006010641A2 (en) 2006-02-02
EP1621536A1 (en) 2006-02-01
AU2005266460A1 (en) 2006-02-02
CN101031559A (zh) 2007-09-05
EA200700141A1 (ru) 2007-08-31
MA28732B1 (fr) 2007-07-02
TW200616973A (en) 2006-06-01
US7759379B2 (en) 2010-07-20
MX2007001024A (es) 2007-04-16
EA011088B1 (ru) 2008-12-30
DE602005026395D1 (de) 2011-03-31
US20080004300A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
PE20060383A1 (es) Nuevos derivados amino de urea ciclicos como inhibidores de quinasa
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
PE20070218A1 (es) COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA
PE20080677A1 (es) Inhibidores de pirrolotriazina cinaza
PE20070790A1 (es) Derivados de 2-aminopirimidina como moduladores de la actividad del receptor de histamina h-4
PE20091095A1 (es) Moduladores de gamma secretasa
PE20060573A1 (es) Derivados de urea ciclicos sustituidos como inhibidores de proteinas quinasas
PE20060374A1 (es) Inhibidores de cinasa heterociclicos fusionados
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
PE20051046A1 (es) Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
PE20060197A1 (es) Heterociclos biciclicos como inhibidores de cinasa
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
PE20110995A1 (es) DERIVADOS DE PIRROLO[3,4-e]PIRIMIDINA COMO INHIBIDORES DE PDE1
PE20080404A1 (es) Derivados bencil-amino-piperidina como inhibidores de cetp
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20080344A1 (es) Compuestos 8-azabiciclo[3.2.1]oct-8-il-1,2,3,4-tetrahidroquinolina sustituidos como inhibidores 11b-hsd1
PE20090718A1 (es) Derivados de espiroindolinona
PE20060679A1 (es) Cis-imidazolinas como inhibidoras de la interaccion de la proteina mdm2 y los polipeptidos similares al p53
PE20120834A1 (es) Derivados de furopirimidindiona como moduladores de trpa1
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
PE20090900A1 (es) Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol como inhibidores del receptor del factor de creciemiento de hepatocitos (met), su procedimiento de preparacion y una composicion farmaceutica que los contiene
PE20080403A1 (es) Derivados heterociclicos fusionados y metodos de uso
PE20080345A1 (es) Derivados de piperazina como agonistas del receptor de gpr38
PE20070848A1 (es) Derivados de pirimidina como ligandos del receptor de histamina h4

Legal Events

Date Code Title Description
FC Refusal